Copyright 1974. All rights reserved

BIOAVAILABILITY OF DRUGS FROM FORMULATIONS AFTER ORAL ADMINISTRATION

*****6579

L. F. Chasseaud and T. Taylor

Department of Metabolism and Pharmacokinetics, Huntingdon Research Centre, Huntingdon, England

An administered drug can elicit only the pharmacologic response for which it was developed, provided that sufficient concentrations of drug reach and are available to the receptors. Determination of the likely availability of the active drug to the receptors is the basis of bioavailability testing. Drugs that are chemically equivalent may not be therapeutically equivalent because of differences in dosage form. Certainly, the more potent the pharmacologic action of the drug, the more imperative is the need for bioavailability testing (1), but only recently has such testing gained acceptance as a worthwhile and necessary adjunct (2–4) to the gamut of tests to which new and existing drugs are subjected.

Among the multiplicity of terms coined in recent years, that of bioavailability has been the subject of much discussion and considerable misunderstanding. Bioavailability, or biologic availability, has been usefully reviewed or discussed by several authors (5-16). Confusion has arisen, however, over interchange of the terms biologic availability (bioavailability), physiologic availability, generic equivalence, and therapeutic equivalence, all of which have been used to define essentially the same events. Bioavailability, which in this decade has become the preferred term, describes the extent to which and the rate at which the active drug reaches the systemic circulation, and ultimately the receptors or sites of action at concentrations that are effective, and thereby defines the efficiency of the dosage formulation as an extravascular drug delivery system. Because it is generally impossible to measure receptor drug concentrations, these are measured in the circulation, venous or arterial, from which the receptors receive their supply. Alternatively, urinary concentrations of the active drug or a characteristic metabolite can be measured (13, 17, 18). There is no guarantee, however, that a drug reaching the systemic circulation will also reach the receptors in adequate concentrations. Sometimes the response of the receptors to the drug may be quantified in controlled clinical trials, for example, the

DOCKE.

RM

36 CHASSEAUD & TAYLOR

lowering of blood sugar by hypoglycemics (19, 20), the excretion of electrolytes after administration of diuretics (21), or the anticoagulant effects of certain coumarins (22), but it is important to know whether the intensity of the pharmacologic effect in a particular case is a function of drug concentration in the body.

VARIATIONS IN BIOAVAILABILITY

In reality, because the drug has to cross several membranes, exist in numerous physiologic environments, and be subjected to tissue uptake, biotransformation, and excretion (18, 23-26), much of an administered dose never reaches the receptors. So that patients are provided with drug formulations that are physically and chemically stable, pharmaceutically reliable, and aesthetically acceptable, drugs are prepared in various physical forms with a number of other ingredients which may influence their bioavailability. To be absorbed from the gastrointestinal tract, the drug must be presented in a soluble form to the site of absorption; for example, an administered tablet must disintegrate and the particles must dissolve in the gastrointestinal milieu before absorption can occur. Different dosage forms of drugs may thus provide varying amounts of the drug for absorption and thereby cause differences in the onset, extent, and duration of pharmacologic effect. These differences may derive from physiologically modified bioavailability and be due to the physiology or pathlogy of the patient and/or his genetic makeup (27), or alternatively from dosage form-modified bioavailability and be due to the methods of manufacture or to the physicochemical properties of the drug (13) (Table 1). This review is mainly concerned with the latter category. For these reasons (Table 1), in vitro tests which do not take into account some of these factors cannot be presumed to predict in vivo drug availability. The in vitro system must be compared against the in vivo case (28) for every formulation type, and in vitro systems are generally only useful for quality control or for the selection of suitable formulations for in vivo testing.

Table 1 Factors affecting bioavailability (13)

Dosage form	Physiologic
Particle size, Polymorphic form, Solvation, Hydration, Chemical form, pH, Solubility characteristics, Formulation adjuvants, Manufacturing method	Age, Sex, Physical state of patient, Time of administration, Stomach emptying, Intestinal motility, Food, Other drugs, Disease

PARAMETERS OF BIOAVAILABILITY

The bioavailability of a drug is characterized by two important parameters: the area under the blood concentration-time relationship and the peak height of this relationship together with its time of occurrence. Figure 1 illustrates the plasma concentration-time relationships for a hypothetical drug which needs to attain a minimum

DOCKE.

BIOAVAILABILITY OF DRUGS 37

concentration in the plasma to be pharmacologically active. Above the maximum safe concentration, a drug such as digoxin (29) causes toxicity. Inspection of the relationships shows that a formulation producing curve I is ineffective, that producing curve II is active and the preferred dosage form, and that producing curve III is active but also leads to toxicity. Similarity of the areas under all three curves in Figure 1 docs not necessarily indicate that the drug will be therapeutically effective in all cases. As a criteria of bioavailability, therefore, both parameters should be considered. Rates of bioavailability are likely to be important for drugs with a low therapeutic index, sparingly soluble drugs, drugs that are destroyed in the gastrointestinal tract or are actively absorbed, or when adequate drug concentrations are required rapidly, as with antibiotics, analgesics, coronary vasodilators, and hypoglycemics. Differences in bioavailability are, however, equivalent to differences in dosage. Suitable reduction in dosage for formulation III and increase in dosage for formulation I should produce a therapeutic and nontoxic response (Figure 1). If bioavailability is estimated from urinary excretion data, suitable parameters are the cumulative excretion of drug (or metabolite) in the urine and the maximum excretion rate and time of its occurrence.



ESTIMATION OF BIOAVAILABILITY

Earlier methods of estimating bioavailability were qualitative, such as monitoring the disintegration of formulations in the gastrointestinal tract (30–32). Disintegration of a formulation or indeed the dissolution of its contents does not provide absolute proof of absorption. The concept of bioavailability was introduced in 1945 (33) during studies of the relative absorption of vitamins from pharmaceutical preparations and was estimated by comparing the fraction of a dose from a test formulation, and that from an aqueous solution, excreted in the urine during a fixed time. An aqueous solution was considered to present the drug in an ideal form for absorption. More generally, bioavailability may be measured as the ratio

Bioavailability = amount of drug absorbed from test formulation amount of drug absorbed from reference formulation

DOCK

38 CHASSEAUD & TAYLOR

where the reference formulation is one from which the drug is readily absorbed, or, preferably, is known to be clinically effective. So measured, bioavailability is a statement of *relative* absorption, not of amount absorbed.

For bioavailability studies, healthy volunteers are preferred to patients because disease states may influence drug bioavailability (34) or elimination (35). Subjects should be selected on the basis of a satisfactory medical examination, normal renal and hepatic function, and freedom from a history of renal, hepatic, gastrointestinal, and endocrine disorders or from a known sensitivity to drugs. Female subjects should be selected only if they are unlikely to be pregnant during or for some time after the studies. The very thin or obese should be excluded so that wide intersubject variations in apparent volumes of distribution are avoided. The use of subjects aged between 18 and 50 years reduces anomalous age-dependent responses (36, 37). Since large intra- and intersubject variations in absorption commonly occur, a sufficient number of subjects, usually 6 to 20, should be used to permit a satisfactory statistical analysis of the data (18, 38-40), and to demonstrate equivalence, a larger number may be necessary. The subjects should give their informed consent and should not be taking other drugs. Equal doses of test and reference formulations should be administered, as plasma concentrations or clearances may not be linearly related to the dose (41, 42). Experimental designs (43) are commonly of a complete crossover type, where every subject receives each formulation according to a random treatment schedule (38). The intensity of the pharmacologic effect of a drug is often nonlinearly related to the logarithm of the administered dose (23) and the therapeutic consequences of changes in dose due to modification of bioavailability may be more serious at lower doses. For this reason acceptable limits of bioavailability must be established for each drug at or near the expected therapeutic dose (13).

Bioavailability is usually estimated from a statistical comparison of either average drug concentrations in the blood (18) or areas to infinite time under the drug concentration-time relationships in the blood after administration of single doses of both test and reference formulations. The duration of sampling is relatively short and improvements in methodology allow accurate determinations of very low drug concentrations. In single-dose studies, sufficient blood samples should be withdrawn to describe adequately the critical phases of the concentration-time relationship: (a) absorption which allows at least a qualitative comparison of the rates of availability, (b) time of occurrence of maximal concentrations, and (c) the decline of concentrations during the elimination phase. During the latter phase, drug concentrations may fall to very low levels, and inadequate analytical procedures could introduce errors into the calculation of areas to infinite time. The precision of the analytical method should be known and the level of sensitivity should exceed the expected peak blood concentration by at least twentyfold. Total areas under the concentration-time curves are usually measured by the trapezoidal rule (44) up to the last sampling time, and the remaining area to infinite time is calculated from the concentration at that time and the observed rate constant for drug elimination from plasma (45). The calculated areas may be normalized (13, 18, 45, 46) to correct for intra- and intersubject variations in dose, body weight, and the apparent elimina-

DOCKET

BIOAVAILABILITY OF DRUGS 39

tion (biological) half-life of the drug. This allows bioavailabilities estimated in studies performed at different times with different subject panels to be validly compared.

Under some circumstances it may be preferable to estimate bioavailability during a sequence of multiple doses, so that experimental conditions resemble the clinical situation (13, 18). After multiple dosing, blood concentrations are greater and more easily measured, but experimental control is more complex. In multiple dose studies, biovailability can be estimated, after attainment of steady state conditions, by comparison of the areas under the blood concentration-time curves during a complete dosage interval or by comparison of maximal and minimal concentrations reached during the dosage interval. This obviates the need for calculation of areas to infinite time, which may be a prime source of error in single-dose studies.

Estimates of bioavailability from urinary excretion data require complete collection of the urine for at least seven drug half-lives, and control of urinary pH may be necessary for certain drugs, such as weak bases (47). Loss of a single sample could invalidate the estimation of bioavailability from measurement of cumulative excretion data, and rates of urinary excretion may not correspond to rates of gastrointestinal absorption. This method is advantageous because the subjects need not undergo numerous venepunctures for blood withdrawal, and drug analysis is simpler, but it should not be used when the drug is extensively biotransformed and less than 20% is excreted in the urine unchanged or as a characteristic metabolite.

All the experimental data obtained should be analyzed by the appropriate statistical procedures (40) with due regard for the methodology used. It should be estimated what differences need to occur between formulations before these are statistically significant.

Seven methods of estimating bioavailability have been described by Wagner & Nelson (48), some of which differ only in the mathematical treatment of the experimental data. Wagner (18) has critically appraised the assumptions involved.

FACTORS AFFECTING BIOAVAILABILITY

Since absorption occurs only after the drug is in solution, orally administered drugs in solid form must first dissolve in the gastrointestinal fluids. The rate at which dissolution occurs is an important determinant of bioavailability and is dependent on several factors. Drugs administered in solid form as capsules or tablets need to disaggregate so that dissolution may occur more readily.



DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

